Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Group 1:Standard therapy plus aerosol inhalation for 3 times (once for every day)
Group 2:Standard therapy plus aerosol inhalation for 3 times (once for every 2 days)
Third group:Standard therapy
Fourth group:Standard therapy plus aerosol inhalation for 6 times (once for every day)
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 70 years old; 2. According with the clinical diagnosis of viral pneumonia symptoms,including fever, Low white blood cells or platelets infiltration shadow in CT; 3. Positive result for nucleic acid of 2019-nCov; 4. Patients can receive aerosol inhalation 5. Consent to sign a written informed statement prior to the beginning of the study.
Exclusion criteria
Exclusion criteria: 1. Pneumonia caused by other viruses, except for 2019-nCov; 2. Clear bacterial infection; 3. Subjects who have used antiviral drugs and may need another antiviral treatment during the study; 4. There are serious non-infectious pulmonary diseases, including tuberculosis, pulmonary edema and pulmonary embolism; 5. Severe liver and kidney dysfunction; 6. Participating in other clinical studies within 30 days before administration; 7. Allergic to type 1 interferon; 8. Pregnant or lactating women; 9.In any other case, if the investigator thinks it is not suitable for the trial, or it may increase the risk of the subject or interfere with the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral load;Clinical features;Inflammation;Pulmonary imaging;In-hospital days; | — |
Secondary
| Measure | Time frame |
|---|---|
| routine blood test;routine urine test;blood biochemical; | — |
Countries
China
Contacts
Public ContactJianqing Xu
Shanghai Public Health Clinical Center
Outcome results
None listed